Takeda Pharmaceutical Company Limited (TYO:4502)
5,582.00
+42.00 (0.76%)
Aug 10, 2026, 3:30 PM JST
Takeda Pharmaceutical Company Employees
Takeda Pharmaceutical Company had 47,029 employees as of March 31, 2026. The number of employees decreased by 426 or -0.90% compared to the previous year.
Employees
47,029
Change (1Y)
-426
Growth (1Y)
-0.90%
Revenue / Employee
98.21M JPY
Profits / Employee
-3.48M JPY
Market Cap
8.91T
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 47,029 | -426 | -0.90% |
| Mar 31, 2025 | 47,455 | -1,826 | -3.71% |
| Mar 31, 2024 | 49,281 | 186 | 0.38% |
| Mar 31, 2023 | 49,095 | 1,748 | 3.69% |
| Mar 31, 2022 | 47,347 | 248 | 0.53% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Eisai | 10,543 |
| Shionogi & | 6,223 |
| Sumitomo Pharma | 4,980 |
| Tsumura & Co. | 4,923 |
| Towa Pharmaceutical | 4,923 |
| Sawai Group Holdings | 3,630 |
| Nippon Shinyaku | 2,309 |
| Kissei Pharmaceutical | 1,786 |
Takeda Pharmaceutical Company News
- 16 hours ago - Takeda award from Veterans Affairs posted to SAM.gov site - TheFly
- 5 days ago - FDA approves Takeda’s Orzeyful to treat narcolepsy type 1 - TheFly
- 5 days ago - U.S. FDA Approves Takeda's ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 - Business Wire
- 5 days ago - US FDA approves Takeda's sleep disorder pill - Reuters
- 11 days ago - Keros Therapeutics to receive $20M elritercept milestone payment from Takeda - TheFly
- 11 days ago - Q1 2027 Takeda Pharmaceutical Co Ltd Earnings Presentation Transcript - GuruFocus
- 11 days ago - Takeda Pharmaceutical Q1 Earnings Call Highlights - MarketBeat
- 11 days ago - Takeda Pharmaceutical Company Earnings Call Transcript: Q1 2027 - Transcripts